Provided by Tiger Fintech (Singapore) Pte. Ltd.

Spero Therapeutics Inc.

0.7542
+0.01421.92%
Post-market: 0.75420.00000.00%17:33 EDT
Volume:35.94K
Turnover:27.62K
Market Cap:42.16M
PE:-0.59
High:0.7860
Open:0.7400
Low:0.7400
Close:0.7400
Loading ...

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

THOMSON REUTERS
·
15 Nov 2024

Spero Therapeutics Inc: Reiterate Cash Runway Into Mid-2026

THOMSON REUTERS
·
15 Nov 2024

Spero Therapeutics Q3 Income From Operation USD -18.593 Million

THOMSON REUTERS
·
15 Nov 2024

Spero Therapeutics Q3 EPS USD -0.32

THOMSON REUTERS
·
15 Nov 2024

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

GlobeNewswire
·
15 Nov 2024

Spero Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
13 Nov 2024

Spero Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
08 Nov 2024

Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth

Zacks
·
06 Nov 2024

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
06 Nov 2024

Spero Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $7

THOMSON REUTERS
·
04 Nov 2024

There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Simply Wall St.
·
02 Nov 2024

Spero Therapeutics Suspends Program for Pulmonary Disease Drug; Plans to Cut Workforce by 39%

MT Newswires Live
·
30 Oct 2024

Spero to cut 39% of workforce on failed study, stock plunges 20%

seekingalpha
·
30 Oct 2024

Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program

Dow Jones
·
30 Oct 2024

Spero suspends development of SPR720, to reduce workforce by 39%

TIPRANKS
·
30 Oct 2024

Spero Therapeutics trading halted, news pending

TIPRANKS
·
30 Oct 2024

Spero Therapeutics Announces Spr720 Phase 2a Interim Results and Provides a Business Update

THOMSON REUTERS
·
30 Oct 2024

Spero Therapeutics Inc - Spr720 Phase 2a Study for Ntm-Pd Fails Primary Endpoint

THOMSON REUTERS
·
30 Oct 2024

Spero Therapeutics Inc - Expects Cash and Funding to Cover Expenses Into Mid-2026

THOMSON REUTERS
·
30 Oct 2024

Spero Therapeutics Inc - to Reduce Workforce by 39% Following Spr720 Program Suspension

THOMSON REUTERS
·
30 Oct 2024